Pfizer halts development of hepatitis C drug filibuvir: report

Pfizer spokeswoman Victoria Davis revealed Friday that the company stopped development of the experimental oral hepatitis C drug filibuvir, also known as PF-00868554, following a strategic review, The Wall Street Journal reported. Davis noted that the decision to halt development of the non-nucleoside polymerase inhibitor, which was in mid-stage testing, was not related to any safety issues.

Analysts were not expecting filibuvir to become a major driver of revenue, and thus The Wall Street Journal noted that the decision to terminate development is not considered a major setback for the drugmaker.

Pfizer was one of several drugmakers working to develop a new all-oral hepatitis C regimen to replace interferon-based therapies. According to The Wall Street Journal, Gilead's regimen could reach the market by 2014, while AbbVie's regimen, which includes a drug in the same category as filibuvir, could be approved in 2015.

To read more Top Story articles, click here.